Cancer clinical trials in the region Île-de-France
660 currently recruiting clinical trials
Looking for clinical trials?
Clinical trial search is a complex process, with countless criteria to consider. Our AI assistant navigates this complexity with precise, expert-level analysis of the most relevant trials based on your medical profile. Our database is fully up to date, so you see only actively recruiting sites. It's fast and easy:
- Create your account
- Copy-paste your latest medical report
- Our AI-based assistant does the rest for you
Whether you are a patient or a doctor, create an account to find and apply for the most relevant clinical trials:
Phase 2
Lung cancer
#NCT03175224
#2024-514542-37-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
MET
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded genetic anomalies
ALK
BRAF
EGFR
KRAS G12C
KRAS non G12C
NTRK-1/2/3
RET
ROS-1
Excluded previous treatments at advanced or metastatic stage
Targeted therapy
5 recruiting sites
Apollomics
Phase 2
Lung cancer
#NCT03175224
#2024-514542-37-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
MET
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Required previous treatments at advanced or metastatic stage
Immunotherapy
Chemotherapy
Excluded genetic anomalies
ALK
BRAF
EGFR
KRAS G12C
KRAS non G12C
NTRK-1/2/3
RET
ROS-1
Excluded previous treatments at advanced or metastatic stage
Targeted therapy
5 recruiting sites
Apollomics
Phase 2
Lung cancer
#NCT03175224
#2024-514542-37-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
MET
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Required previous treatments at advanced or metastatic stage
Immunotherapy
Chemotherapy
Excluded genetic anomalies
ALK
BRAF
EGFR
KRAS G12C
KRAS non G12C
NTRK-1/2/3
RET
ROS-1
Excluded previous treatments at advanced or metastatic stage
Targeted therapy
5 recruiting sites
Apollomics
Phase 2
Breast cancer
Prostate cancer
Colon cancer
Rectal cancer
Kidney cancer
Pancreas cancer
Liver and bile duct cancer
Bladder / Urinary Tract / Urethral cancer
Stomach and esophageal cancer
Endometrial cancer
Ovarian / Fallopian tubes / Peritoneum cancer
Head and neck cancer
Sarcoma and GIST
Thymus cancer
Penile cancer and germ cell tumors
Cervical / Vulvar / Vaginal cancer
Small intestine and appendix cancer
Thyroid and adrenal gland cancer
#NCT03175224
#2024-514542-37-00
Cohortes C, D
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
MET
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Excluded genetic anomalies
BRAF
EGFR
KRAS G12C
KRAS non G12C
NTRK-1/2/3
RET
ALK
ROS-1
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Targeted therapy
5 recruiting sites
Apollomics
Phase 2
Breast cancer
Lung cancer
Prostate cancer
Colon cancer
Rectal cancer
Anal cancer
Kidney cancer
Pancreas cancer
Liver and bile duct cancer
Bladder / Urinary Tract / Urethral cancer
Stomach and esophageal cancer
Endometrial cancer
Ovarian / Fallopian tubes / Peritoneum cancer
Head and neck cancer
Sarcoma and GIST
Thymus cancer
Penile cancer and germ cell tumors
Cervical / Vulvar / Vaginal cancer
Small intestine and appendix cancer
Thyroid and adrenal gland cancer
Brain tumors / Central nervous system tumors
#NCT03175224
#2024-514542-37-00
Required number of previous lines of therapy
1
2
3 or more
Excluded genetic anomalies
ALK
BRAF
EGFR
KRAS G12C
KRAS non G12C
MET
NTRK-1/2/3
RET
ROS-1
Excluded previous treatments
Systemic Treatment-Naive
5 recruiting sites
Apollomics
Phase 2
Brain tumors / Central nervous system tumors
#NCT03175224
#2024-514542-37-00
Required genetic anomalies
MET
Required number of previous lines of therapy
1
2
3 or more
Excluded genetic anomalies
BRAF
EGFR
NTRK-1/2/3
ALK
KRAS G12C
KRAS non G12C
RET
ROS-1
Excluded previous treatments
Systemic Treatment-Naive
5 recruiting sites
Apollomics
Phase 2
Endometrial cancer
#NCT05548296
#2025-524542-10-00
Required histologic sub types
Serous adenocarcinoma
Required disease stage
Metastatic
Required number of previous lines of therapy for current stage of disease
1
2
Required previous treatments at advanced or metastatic stage
Immunotherapy
Chemotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
4 recruiting sites
Acrivon Therapeutics
Phase 2
Multiple myeloma
#NCT07227311
#2025-523117-28-00
Cohorte BVd (Belantamab mafodotin + Bortezomib + Dexamethasone)
Required histologic types
Symptomatic multiple myeloma
Required histologic sub types
Monoclonal component measurable
Required number of previous lines of therapy
1
2
Excluded previous treatments
Systemic Treatment-Naive
Allogeneic stem cell transplant
3 recruiting sites
GlaxoSmithKline
Phase 2
Multiple myeloma
#NCT07227311
#2025-523117-28-00
Cohorte BKd (Belantamab mafodotin + Carfilzomib + dexaméthasone)
Required histologic types
Symptomatic multiple myeloma
Required histologic sub types
Monoclonal component measurable
Required number of previous lines of therapy
1
2
Excluded previous treatments
Systemic Treatment-Naive
Allogeneic stem cell transplant
2 recruiting sites
GlaxoSmithKline
Phase 2
Multiple myeloma
#NCT07227311
#2025-523117-28-00
Cohorte BPd (Belantamab + Pomalidomide + Dexamethasone))
Required histologic types
Symptomatic multiple myeloma
Required histologic sub types
Monoclonal component measurable
Required number of previous lines of therapy
1
2
Required previous treatments
Immunomodulator
Excluded previous treatments
Systemic Treatment-Naive
Allogeneic stem cell transplant
2 recruiting sites
GlaxoSmithKline